Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells

被引：31

作者：

Yu, Xinyi ^{[1
,2
,3
,4
,5
,6
,7
]}

Liu, Feng ^{[7
,8
]}

Zeng, Liyi ^{[7
,9
,10
]}

He, Fang ^{[1
,2
,3
,4
,5
,6
,7
]}

Zhang, Ruyi ^{[7
,11
,12
]}

Yan, Shujuan ^{[7
,11
,12
]}

Zeng, Zongyue ^{[7
,11
,12
]}

Shu, Yi ^{[7
,8
,11
,12
]}

Zhao, Chen ^{[1
,2
,3
,4
,5
,6
,7
]}

Wu, Xingye ^{[1
,2
,3
,4
,5
,6
,7
]}

Lei, Jiayan ^{[1
,2
,3
,4
,5
,6
,7
]}

Zhang, Wenwen ^{[7
,13
]}

Yang, Chao ^{[7
,8
]}

Wu, Ke ^{[7
,8
]}

Wu, Ying ^{[7
,14
]}

An, Liping ^{[7
,15
,16
]}

Huang, Shifeng ^{[1
,2
,3
,4
,5
,6
,7
]}

Ji, Xiaojuan ^{[7
,8
]}

Gong, Cheng ^{[7
,17
]}

Yuan, Chengfu ^{[7
,18
]}

Zhang, Linghuan ^{[7
,8
]}

Feng, Yixiao ^{[1
,2
,3
,4
,5
,6
,7
]}

Huang, Bo ^{[7
,9
,10
,19
]}

Liu, Wei ^{[1
,2
,3
,4
,5
,6
,7
]}

Zhang, Bo ^{[7
,15
,16
]}

Dai, Zhengyu ^{[7
,20
]}

Wang, Xi ^{[7
,11
,12
]}

Liu, Bo ^{[1
,2
,3
,4
,5
,6
,7
]}

Haydon, Rex C. ^{[7
]}

Luu, Hue H. ^{[7
]}

Gan, Hua ^{[1
,2
,3
,4
,5
,6
]}

He, Tong-Chuan ^{[7
]}

Chen, Liqun ^{[1
,2
,3
,4
,5
,6
,7
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China

[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing, Peoples R China

[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China

[4] Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing, Peoples R China

[5] Chongqing Med Univ, Affiliated Hosp 1, Dept Plast Surg, Chongqing, Peoples R China

[6] Chongqing Med Univ, Affiliated Hosp 1, Dept Clin Lab Med, Chongqing, Peoples R China

[7] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA

[8] Chongqing Med Univ, Childrens Hosp, Stem Cell Biol & Therapy Lab, Minist Educ,Key Lab Child Dev & Disorders, Chongqing, Peoples R China

[9] Cent S Univ, Zhuzhou Cent Hosp, Dept Infect Control, Zhuzhou, Peoples R China

[10] Cent S Univ, Xiangya Med Coll, Affiliated Zhuzhou Hosp, Zhuzhou, Peoples R China

[11] Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing, Peoples R China

[12] Chongqing Med Univ, Sch Lab Med, Chongqing, Peoples R China

[13] Chongqing Med Univ, Affiliated Univ Town Hosp, Dept Obstet & Gynecol, Chongqing, Peoples R China

[14] Beijing Univ Chinese Med, Dept Immunol & Microbiol, Beijing, Peoples R China

[15] Lanzhou Univ, Key Lab Orthopaed Surg Gansu Prov, Hosp 2, Lanzhou, Gansu, Peoples R China

[16] Lanzhou Univ, Dept Orthopaed Surg, Hosp 2, Lanzhou, Gansu, Peoples R China

[17] Wuhan Univ, Dept Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China

[18] China Three Gorges Univ, Dept Biochem & Mol Biol, Sch Med, Yichang, Peoples R China

[19] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab Med, Nanchang, Jiangxi, Peoples R China

[20] Chongqing Hosp Tradit Chinese Med, Dept Orthopaed Surg, Chongqing, Peoples R China

来源：

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY | 2018年 / 47卷 / 03期

基金：

美国国家卫生研究院;

关键词：

Niclosamide; Renal cell carcinoma; Kidney cancer; Drug repurposing; Metastatic renal cancer; Targeted therapy; HUMAN OSTEOSARCOMA GROWTH; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN PATHWAY; OVARIAN-CANCER; KIDNEY CANCER; STEM-CELLS; RESISTANCE; INHIBITION; THERAPY; DIFFERENTIATION;

D O I：

10.1159/000490140

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Background/Aims: As the most lethal urological cancers, renal cell carcinoma (RCC) comprises a heterogeneous group of cancer with diverse genetic and molecular alterations. There is an unmet clinical need to develop efficacious therapeutics for advanced, metastatic and/or relapsed RCC. Here, we investigate whether anthelmintic drug Niclosamide exhibits anticancer activity and synergizes with targeted therapy Sorafenib in suppressing RCC cell proliferation. Methods: Cell proliferation and migration were assessed by Crystal violet staining, WST-1 assay, cell wounding and cell cycle analysis. Gene expression was assessed by qPCR. In vivo anticancer activity was assessed in xenograft tumor model. Results: We find that Niclosamide effectively inhibits cell proliferation, cell migration and cell cycle progression, and induces apoptosis in human renal cancer cells. Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells. Niclosamide is further shown to synergize with Sorafenib in suppressing RCC cell proliferation and survival. In the xenograft tumor model, Niclosamide is shown to effectively inhibit tumor growth and suppress RCC cell proliferation. Conclusions: Niclosamide may be repurposed as a potent anticancer agent, which can potentiate the anticancer activity of the other agents targeting different signaling pathways in the treatment of human RCC. (C) 2018 The Author(s) Published by S. Karger AG, Basel

引用

页码：957 / 971

页数：15

共 50 条

[11] Ramelteon Exhibits Anticancer Effects in Different Types of Human Cancer Cells
Turkol, Senanur
Keskin, Tuba
Sekerci, Guldeniz
Tekin, Cigdem
Tekin, Suat
ACTA PHYSIOLOGICA, 2025, 241 : 40 - 40
[12] Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
Shi, Lingyi
Zheng, Hailun
Hu, Wanle
Zhou, Bin
Dai, Xuanxuan
Zhang, Yi
Liu, Zhiguo
Wu, Xiaoping
Zhao, Chengguang
Liang, Guang
ONCOTARGETS AND THERAPY, 2017, 10 : 1767 - 1776
[13] Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells
Srivastava, Akhil
Amreddy, Narsireddy
Babu, Anish
Panneerselvam, Janani
Mehta, Meghna
Muralidharan, Ranganayaki
Chen, Allshine
Zhao, Yan Daniel
Razaq, Mohammad
Riedinger, Natascha
Kim, Hogyoung
Liu, Shaorong
Wu, Si
Abdel-Mageed, Asim B.
Munshi, Anupama
Ramesh, Rajagopal
SCIENTIFIC REPORTS, 2016, 6
[14] Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells
Akhil Srivastava
Narsireddy Amreddy
Anish Babu
Janani Panneerselvam
Meghna Mehta
Ranganayaki Muralidharan
Allshine Chen
Yan Daniel Zhao
Mohammad Razaq
Natascha Riedinger
Hogyoung Kim
Shaorong Liu
Si Wu
Asim B. Abdel-Mageed
Anupama Munshi
Rajagopal Ramesh
Scientific Reports, 6
[15] Potent anticancer activity of a new bismuth (III) complex against human lung cancer cells
Ouyang, Ruizhuo
Yang, Yang
Tong, Xiao
Feng, Kai
Yang, Yaoqin
Tao, Huihong
Zhang, Xiaoshen
Zong, Tianyu
Cao, Penghui
Xiong, Fei
Guo, Ning
Li, Yuhao
Miao, Yuqing
Zhou, Shuang
JOURNAL OF INORGANIC BIOCHEMISTRY, 2017, 168 : 18 - 26
[16] Anticancer Activity of Sorafenib in Combined Treatment with Betulin in Human Non-Small Cell Lung Cancer Cell Lines
Kutkowska, Justyna
Ziolo, Ewa
Rapak, Andrzej
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1285 - S1285
[17] Propolis from the North-East region of India exhibits potent antioxidant and anticancer activity against breast cancer cells
Rahman, Seydur
Talukdar, Narayan Chandra
Patowary, Kaustuvmani
Mohanta, Yugal Kishore
BIOCATALYSIS AND AGRICULTURAL BIOTECHNOLOGY, 2024, 59
[18] Pre-treatment with histone deacetylase inhibitor HDACI) synergizes the anti-cancer effect of sorafenib in renal cell carcinoma cells
Kim, Dong Eun
Kim, Mi Joung
Jang, Sejin
Lee, Je-Hwan
Choi, Jene
Ro, Seonggu
Kim, Choung-Soo
Hwang, Jung Jin
CANCER RESEARCH, 2011, 71
[19] Boric Acid Exhibits Anticancer Properties in Human Endometrial Cancer Ishikawa Cells
Gundogdu, Ayse Cakor
Ari, Neziha Senem
Hobel, Asiye
Eldiven, Omer
Kar, Fatih
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
[20] Globularifolin exhibits potent anticancer activity on A549 human lung cancer cell line via induction of mitochondrial apoptosis, cell cycle arrest and NF-κB inhibition
Zeng, Yingou
Zhang, Yongming
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (03): : 1758 - 1764

← 1 2 3 4 5 →